BioNTech and Pfizer have announced that they are initiating a phase 1 study to evaluate a single dose mRNA-based combination vaccine candidate against influenza and COVID-19 – a novel ...

The decision to move into phase 3 testing follows the completion of various phase 1 studies that backed the drug's safety, tolerability, and pharmacokinetics, according to Roche. The drug ...

fDepartment of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China ...